Adjuvant Immunotherapy

Emerging role of adjuvant immunotherapy in oncology

Neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer

Leveraging Neoadjuvant and Adjuvant Immunotherapy to Improve Outcomes in Early-Stage Cancers

PeerView Oncology

Differences in treating lung cancer with adjuvant and neoadjuvant immunotherapy

Adjuvant pembrolizumab improves RCC disease-free survival | Toni Choueiri

Medicine Matters oncology

Adherence to adjuvant immunotherapy and TKIs in resected in NSCLC

Dr. Weber on Adjuvant Pembrolizumab in Melanoma

Results from KEYNOTE-716: adjuvant therapy with pembrolizumab in high-risk stage II melanoma

Dr. Gupta Discusses Adjuvant Immunotherapy in Kidney Cancer

Adjuvant Immunotherapy: The IMVigor Trials - Bladder Cancer Video Library

GRACE - Global Resource for Advancing Cancer Education

Adjuvant and neoadjuvant immunotherapy in MCC

Managing immune-related adverse events in adjuvant immunotherapy

#ESMO22 Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma:SWOG S1801

European Society for Medical Oncology (ESMO)

Adjuvant therapy for Melanoma - Amaria

Management of Esophageal/GEJ Cancers: An Interdisciplinary Tumor Board on Adjuvant Immunotherapy

PeerView Oncology

Is adjuvant immunotherapy necessary in non-small cell lung cancer?

The Potential for Adjuvant Immunotherapy for NSCLC

Dr. Rini on Adjuvant Immunotherapy in Renal Cell Carcinoma

Adjuvant Immunotherapy: Questions/Concerns - Leading Developments & Current Questions in Lung Cancer

GRACE - Global Resource for Advancing Cancer Education

Dr. Pavlick on Adjuvant Immunotherapy in High-risk Melanoma